Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Cannabidiol for Reduction of Brain Neuroinflammation
NCT05066308Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2022
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cannabidiol in chronic low back pain (CLBP), major depressive disorder (MDD), sponsored by Massachusetts General Hospital. Started Jan 2022; status: completed.
02
Drugs
cannabidiol
03
Conditions
chronic low back pain (CLBP)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05066308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05066308.